William Blair Investment Management LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 2.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,121 shares of the company’s stock after selling 1,907 shares during the period. William Blair Investment Management LLC owned 0.08% of IDEXX Laboratories worth $32,701,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Riverview Trust Co acquired a new stake in IDEXX Laboratories during the first quarter worth $26,000. Crewe Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 1st quarter worth $26,000. Ridgewood Investments LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $27,000. Institutional & Family Asset Management LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $28,000. Finally, DSM Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $33,000. Institutional investors and hedge funds own 87.84% of the company’s stock.
IDEXX Laboratories Trading Up 0.7 %
NASDAQ IDXX opened at $500.55 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The firm has a 50 day moving average of $481.18 and a two-hundred day moving average of $501.22. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $41.20 billion, a PE ratio of 48.46, a price-to-earnings-growth ratio of 4.17 and a beta of 1.33.
Analyst Ratings Changes
Several equities research analysts recently issued reports on IDXX shares. Piper Sandler cut their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, BTIG Research began coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $582.25.
Get Our Latest Report on IDEXX Laboratories
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- How to Use the MarketBeat Stock Screener
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 9/9 – 9/13
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.